The effect of date seed powder supplementation on glycaemic markers and lipid profile in women with overweight and obesity: a randomised controlled trial

Hashemzadeh, Maral; Shojaei‐Zarghani, Sara; Miri, Hamid Heidarian; Kazemi, Asma

doi:10.1111/ijfs.16428

Cited by 1 publication

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study indicated that consumption of DSP for 8 weeks significantly decreased HbA1c, insulin, HOMA-IR, and HOMA-B; in addition, QUICK increased in diabetic patients consuming DSP. Consistently, Hashemzadeh et al stated that 12-weeks administration of DSP supplements (200 mg twice a day) considerably reduced FPG and HbA1c levels in overweight and obese women suffering from type 2 diabetes [ 29 ]. Following the DSP consumption, the reduction in FPG was marginally significant and the reduction of HbA1c was not clinically relevant, which may be attributed to the duration of the intervention that could not show the beneficial changes in this parameter.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of date seed on glycemia and advanced glycation end-products in type 2 diabetes: a randomized placebo-controlled trial

Mohamadizadeh,

Dehghan,

Azizi-Soleiman

et al. 2024

Nutr. Diabetes

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) is a chronic medical condition affecting more than 95% of people with diabetes. Traditionally, some medicinal plants have been considered as an effective approach in management of T2DM. This trial evaluated the effects of date seed powder (DSP) on glycemia indices and oxidative stress in T2DM patients. Methods In this trail, 43 patients with T2DM were randomized to two groups: either 5 g/d of the DSP or placebo for 8 weeks. Levels of glycemic indices, lipolpolysaccharide (LPS), and soluble receptor for advanced glycation end products (s-RAGE), as well as other parameters associated with oxidative stress were assessed at baseline and after 8 weeks. Independent t-test and analysis of covariance (ANCOVA) were used for between-groups comparisons at baseline and the post-intervention phase, respectively. Results The results showed that supplementation with DSP significantly decreased HbA1c (−0.30 ± 0.48%), insulin (−1.70 ± 2.21 μU/ml), HOMA-IR (−1.05 ± 0.21), HOMA-B (−0.76 ± 21.21), lipopolysaccharide (LPS) (−3.68 ± 6.05 EU/mL), and pentosidine (118.99 ± 21.67 pg/mL) (P < 0.05, ANCOVA adjusted for baseline and confounding factors). On the other hand, DSP supplementation significantly increased total antioxidant capacity (TAC) (0.50 ± 0.26 mmol/L), superoxide dismutase (SOD) (0.69 ± 0.32 U/ml), and s-RAGE (240.13 ± 54.25 pg/mL) compared to the placebo group. FPG, hs-CRP, GPx, CML, and uric acid had no significant within- or between-group changes. Conclusion Supplementation of DSP could be considered an effective strategy to improve glycemic control and oxidative stress in T2DM patients (Registration ID at www.irct.ir: IRCT20150205020965N10).

show abstract

Section: Discussionmentioning

confidence: 99%